Xavier Forns
#136,776
Most Influential Person Now
Researcher
Xavier Forns's AcademicInfluence.com Rankings
Xavier Fornscomputer-science Degrees
Computer Science
#6317
World Rank
#6663
Historical Rank
Machine Learning
#2007
World Rank
#2033
Historical Rank
Artificial Intelligence
#2258
World Rank
#2297
Historical Rank
Database
#3415
World Rank
#3558
Historical Rank
Download Badge
Computer Science
Xavier Forns's Degrees
- PhD Computer Science University of Barcelona
- Masters Computer Science University of Barcelona
- Bachelors Computer Science University of Barcelona
Similar Degrees You Can Earn
Why Is Xavier Forns Influential?
(Suggest an Edit or Addition)Xavier Forns's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018) (2085)
- EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009) (1471)
- Non-invasive evaluation of liver fibrosis using transient elastography. (2008) (1273)
- EASL Recommendations on Treatment of Hepatitis C 2016. (2017) (1167)
- Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model (2002) (1132)
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016) (878)
- EASL Recommendations on Treatment of Hepatitis C 2015. (2015) (791)
- Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis (1994) (565)
- Hepatitis C virus kinetics during and immediately after liver transplantation (2002) (511)
- EASL Clinical Practice Guidelines: Liver transplantation. (2016) (502)
- Noninvasive assessment of liver fibrosis (2011) (495)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation (2006) (428)
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. (2016) (425)
- An interferon-free antiviral regimen for HCV after liver transplantation. (2014) (396)
- Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. (2004) (346)
- Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. (2007) (345)
- Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. (2015) (339)
- Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. (2015) (336)
- Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. (2003) (312)
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. (2017) (300)
- Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (2006) (292)
- Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. (2014) (287)
- Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy: Analysis of 257 Cases (2011) (264)
- Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. (2012) (256)
- Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation (2015) (216)
- Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. (2017) (202)
- Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. (2009) (190)
- Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation (2004) (187)
- Viral hepatitis in liver transplantation. (2012) (172)
- Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. (2000) (171)
- Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection (2018) (159)
- ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. (2012) (157)
- Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus (HCV) Envelope E2 Protein Modified the Infection After Challenge With Homologous Monoclonal HCV (2000) (155)
- Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. (2011) (154)
- Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). (2006) (149)
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. (2015) (147)
- Quasispecies in viral persistence and pathogenesis of hepatitis C virus. (1999) (146)
- Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans (2010) (143)
- Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation (2010) (140)
- Systemic Autoimmune Diseases in Patients with Hepatitis C Virus Infection: Characterization of 1020 Cases (The HISPAMEC Registry) (2009) (137)
- Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. (2008) (136)
- Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) (128)
- Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. (1997) (125)
- The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. (1998) (123)
- EASL recommendations on treatment of hepatitis C 2014. (2014) (123)
- Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct‐Acting Antivirals (2017) (109)
- Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension (2017) (108)
- Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. (2009) (108)
- Severe Autoimmune Cytopenias in Treatment-Naive Hepatitis C Virus Infection: Clinical Description of 35 Cases (2003) (108)
- Recommendations on Treatment of Hepatitis C 2015 (2015) (102)
- Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C (2018) (99)
- Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C (2011) (99)
- Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. (2016) (97)
- The molecular biology of hepatitis C virus. Genotypes and quasispecies. (1999) (95)
- Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. (2006) (95)
- Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. (2017) (93)
- Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. (2005) (90)
- Beneficial Effect of Angiotensin-Blocking Agents on Graft Fibrosis in Hepatitis C Recurrence after Liver Transplantation (2004) (89)
- A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C (2012) (88)
- Donor and Recipient IL28B Polymorphisms in HCV‐Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation (2011) (87)
- Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals. (2020) (86)
- Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1 (2012) (86)
- Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. (2017) (85)
- High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods (2014) (78)
- Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. (2020) (75)
- DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. (1999) (74)
- Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment (2009) (74)
- Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. (2010) (74)
- Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? (2017) (73)
- O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY (2014) (73)
- Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. (2005) (72)
- The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. (2018) (71)
- The challenge of developing a vaccine against hepatitis C virus. (2002) (71)
- Studies of Hepatitis C Virus in Chimpanzees and Their Importance for Vaccine Development (2001) (71)
- G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial (2015) (69)
- Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. (2014) (69)
- Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. (2018) (68)
- HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans (2014) (68)
- Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy (2012) (67)
- Nosocomial transmission of HCV in the liver unit of a tertiary care center (2005) (67)
- How Escherichia coli can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure. (1997) (67)
- Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. (2018) (66)
- High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: Frequent mixed infections with different genotypes and lack of evidence of associated liver disease (1999) (64)
- Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. (1999) (63)
- Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. (2018) (63)
- Retransplantation in patients with hepatitis C recurrence after liver transplantation. (2010) (63)
- Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. (2001) (61)
- Life-Threatening Cryoglobulinemic Patients With Hepatitis C (2013) (60)
- Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. (2015) (60)
- Evolution of hepatitis C virus quasispecies immediately following liver transplantation (2004) (59)
- MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection (2017) (58)
- Hepatitis C Virus Compartmentalization and Infection Recurrence after Liver Transplantation (2009) (58)
- Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. (1996) (57)
- Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. (2019) (56)
- Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. (2000) (56)
- Disulfiram-induced hepatitis. Report of four cases and review of the literature. (1994) (55)
- Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit. (1997) (54)
- Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients (1996) (54)
- High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV‐1b–related cirrhosis (2001) (53)
- Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C (2006) (53)
- Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy (2020) (52)
- Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C (2014) (51)
- Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. (2000) (50)
- Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy. (1997) (50)
- Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. (2013) (49)
- Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti‐viral therapy with an interferon‐free regimen (2017) (47)
- Virology and pathogenesis of hepatitis C virus recurrence (2008) (47)
- Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. (2017) (47)
- Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis (2021) (46)
- Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response (2010) (45)
- Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. (2006) (45)
- 869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial (2013) (43)
- Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes (2020) (43)
- Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. (1996) (43)
- Hepatitis C virus receptors claudin‐1 and occludin after liver transplantation and influence on early viral kinetics (2011) (43)
- Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ⇑ (2015) (43)
- Management of ascites and renal failure in cirrhosis. (1994) (42)
- [Hepatitis C in Spain]. (2006) (41)
- Prevention and treatment of hepatitis C virus recurrence after liver transplantation. (2004) (41)
- New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C (2013) (41)
- Hepatitis A outbreak in Barcelona among men who have sex with men (MSM), January‐June 2017: A hospital perspective (2018) (41)
- O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION (2014) (40)
- Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies (2013) (40)
- Hepatitis G virus infection in a haemodialysis unit: prevalence and clinical implications. (1997) (40)
- DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. (2002) (40)
- Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. (2010) (40)
- Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients (2020) (39)
- Hepatitis G virus infection in chronic liver disease (1998) (38)
- Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. (2016) (38)
- Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C (2001) (37)
- 1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (2007) (37)
- Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. (2010) (37)
- Interferon-Free Regimens in the Liver-Transplant Setting (2014) (36)
- 136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1 (2003) (35)
- HCV virological assessment. (2006) (35)
- Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). (2021) (34)
- Anti‐viral therapy can be delayed or avoided in a significant proportion of HBeAg‐negative Caucasian patients in the Grey Zone (2018) (32)
- LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension (2015) (31)
- Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. (2014) (31)
- Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061 (2005) (31)
- [Use of complementary and alternative medicine in patients with chronic hepatitis C]. (2004) (29)
- 365 Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial (2015) (29)
- How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients (2015) (29)
- O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION (2014) (29)
- P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY (2014) (29)
- Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. (2019) (28)
- Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV‐RNA viraemia and HIV coinfection (2007) (27)
- Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation (2016) (26)
- 226 Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the Solar 1 and Solar 2 Trials (2015) (26)
- Virological analysis of patients receiving Telaprevir administered Q8H or Q12H with Peginterferon-Alfa-2A or -Alfa-2B and Ribavirin in treatment-naive patients with Genotype I hepatitis C: study C208 (2009) (26)
- Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease (2017) (26)
- Hepatitis G virus infection in fulminant hepatic failure (1997) (25)
- High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent Hcv Genotype 1 Infection Receiving Abt-450/r/ombitasvir+dasabuvir Plus Ribavirin: 198 (2014) (25)
- Treatment of HCV infection in patients with advanced cirrhosis (2004) (25)
- Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection (2017) (23)
- Clinical trial watch: reports from the AASLD Liver Meeting®, Boston, November 2014. (2015) (22)
- Interplay between Basic Residues of Hepatitis C Virus Glycoprotein E2 with Viral Receptors, Neutralizing Antibodies and Lipoproteins (2012) (21)
- Selective Inhibition of Hepatitis C Virus Infection by Hydroxyzine and Benztropine (2014) (21)
- Decompensation in advanced non-alcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels that in patients with viral disease. (2021) (21)
- PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. (2014) (21)
- Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals (2020) (21)
- Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies (2015) (20)
- A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients (2017) (20)
- Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. (2012) (20)
- Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation (2013) (20)
- HEV infection in two referral centers in Spain: epidemiology and clinical outcomes. (2015) (20)
- SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain (2020) (20)
- Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV‐decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list (2015) (20)
- Cell Culture Replication of a Genotype 1b Hepatitis C Virus Isolate Cloned from a Patient Who Underwent Liver Transplantation (2011) (19)
- Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. (2016) (19)
- P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials (2015) (18)
- HCV‐Positive Donor Organs in Solid Organ Transplantation: “Mind the Gap!” (2017) (18)
- Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. (2000) (18)
- O004 : On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II saturn study (2015) (17)
- Comparative study of a modified competitive RT‐PCR and amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum (1999) (17)
- Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing. (2017) (17)
- Therapy: Statins and liver disease: from concern to 'wonder' drugs? (2015) (17)
- Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). (2019) (17)
- Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis (2015) (17)
- [Hepatic angiosarcoma: a report of a case associated with treatment with arsenic salts and a review of the literature]. (1995) (16)
- Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy (2017) (15)
- Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture (2021) (15)
- P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION (2014) (15)
- Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents (2016) (14)
- Severity of Liver Disease Affects HCV Kinetics in Patients Treated with Intravenous Silibinin Monotherapy (2014) (14)
- Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. (2009) (14)
- EASL Meeting Report Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis q (2006) (14)
- High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4 (2017) (14)
- Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth (2017) (14)
- Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia (2015) (14)
- Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection (2006) (14)
- Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis (2019) (14)
- Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation (2018) (14)
- Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. (2017) (13)
- Lack of a 5.9 kDa Peptide C-Terminal Fragment of Fibrinogen α Chain Precedes Fibrosis Progression in Patients with Liver Disease (2014) (13)
- Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection (2015) (13)
- MR elastography to assess liver fibrosis. (2008) (13)
- Hepatitis C virus infection inhibits P-body granule formation in human livers. (2015) (13)
- Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C (2016) (13)
- Treating hepatitis C in patients with cirrhosis: the effort is worth it. (2010) (13)
- Early non‐invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation (2016) (13)
- 56 ON-TREATMENT RESPONSE-GUIDED THERAPY WITH TELAPREVIR Q8H OR Q12H COMBINED WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C (STUDY C208) (2010) (12)
- Amyotrophic Lateral Sclerosis in a Patient ivith Systemic Lupus Erythematosus (1993) (12)
- The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. (2015) (12)
- Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat? (2007) (12)
- Incidence of depression in patients with hepatitis C treated with direct-acting antivirals (2019) (12)
- Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation (2018) (12)
- Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. (1996) (11)
- Evolution of the NS3 and NS5B Regions of the Hepatitis C Virus During Disease Recurrence After Liver Transplantation (2007) (11)
- Value of duplex-doppler ultrasound findings in liver transplant recipients with initial poor graft function (1996) (11)
- Liver transplant immunosuppression during the covid-19 pandemic. (2020) (11)
- Non-invasive tests for clinically significant portal hypertension after HCV cure. (2022) (11)
- Characterization of the Cross‐Neutralizing Antibody Response Against Hepatitis C Virus in the Liver Transplantation Setting (2011) (10)
- Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors. (2015) (10)
- Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. (2014) (10)
- Evaluation of commercially available and in-house reverse transcription-PCR assays for detection of hepatitis G virus or GB virus C (1997) (10)
- Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). (2018) (10)
- Systematic review with meta‐analysis: neuroimaging in hepatitis C chronic infection (2018) (10)
- Hepatitis C virus early kinetics and resistance‐associated substitution dynamics during antiviral therapy with direct‐acting antivirals (2018) (10)
- Undetectable HCV‐RNA at treatment‐week 8 results in high‐sustained virological response in HCV G1 treatment‐experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program (2015) (10)
- Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false‐positive antibodies (2019) (10)
- Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. (2015) (9)
- EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (2017) (9)
- Hemodynamic response to propranolol in patients with recurrent hepatitis C virus–related cirrhosis after liver transplantation: A case‐control study (2013) (9)
- Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future. (2020) (9)
- Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. (2014) (9)
- Imaging of hepatitis C virus infection in liver grafts after liver transplantation. (2013) (8)
- A Gaussia Luciferase Cell-Based System to Assess the Infection of Cell Culture- and Serum-Derived Hepatitis C Virus (2012) (8)
- Can we identify liver fibrosis in HCV-infected patients without a liver biopsy? (2003) (8)
- Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease (2016) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- 150 Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation (2006) (8)
- [Adult living donor liver transplantation. Analysis of the first 30 cases]. (2003) (8)
- Performance of Hepatitis C Virus Core Antigen Immunoassay in Monitoring Viral Load after Liver Transplantation (2005) (8)
- Efficacy of an accelerated double‐dose hepatitis B vaccine regimen in patients with cirrhosis (2021) (7)
- Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct‐acting anti‐virals (2020) (7)
- GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection: 888 (2016) (7)
- Simple prediction of long‐term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation (2016) (7)
- Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy (2020) (7)
- Occult Hepatitis C Virus Infection: Are We Digging Too Deep? (2016) (7)
- Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". (2016) (7)
- YAMATO: The First SDN Control Plane for Independent, Joint, and Fractional-Joint Switched SDM Optical Networks (2017) (7)
- O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy (2015) (7)
- The extrahepatic contribution to HCV plasma viremia. (2006) (7)
- Amyotrophic lateral sclerosis in a patient with systemic lupus erythematosus. (1993) (7)
- Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study (2017) (7)
- Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies (2016) (7)
- Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. (2012) (7)
- Interferon free regimens for the "difficult-to-treat": are we there? (2013) (7)
- Hepatitis C virus and human immunodeficiency virus: The Un‐Won Battle (2007) (7)
- Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors (2013) (7)
- Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy (2011) (7)
- Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and HCV primary liver transplantation: a case–control study (2014) (7)
- On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study (2016) (6)
- Cyclosporine A or Tacrolimus for Hepatitis C Recurrence? An Old Debate (2011) (6)
- Hepatitis C treatment for patients post liver transplant (2015) (6)
- Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts (2021) (6)
- Severe hepatitis B reactivation during direct-acting antiviral treatment in "the absence" of hepatitis B surface antigen. (2019) (6)
- Simeprevir plus Sofosbuvir for Hepatitis C Virus Genotype 4 Infection: A Phase 3, Open-Label Study (2016) (6)
- P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation (2015) (6)
- Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. (2015) (5)
- Expected developments in hepatology. (2002) (5)
- Interferon (INF)-Free Antiviral Therapy in Cirrhotic Patients Infected with Hepatitis C on the Waiting List for Liver Transplantation. Efficacy and Impact on Delisting and Liver Function (2016) (5)
- Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study (2021) (5)
- Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules (2021) (5)
- Phase 2 study of Telaprevir administered Q8 or Q12H with Peginterferon-Alfa-2A or Alfa-2B and ribavirin in treatment-naive subjects with genotype 1 hepatitis C: week 4 interim results (2008) (5)
- Elastography is unable to exclude cirrhosis after sustained virological response in HCV‐infected patients with advanced chronic liver disease (2021) (5)
- Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. (2015) (5)
- Fanconi syndrome due to tenofovir disoproxil fumarate (TDF) after liver transplantation. (2019) (5)
- Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C) (2016) (5)
- IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. (2014) (5)
- Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population (2020) (5)
- Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". (2015) (5)
- Viral eradication and fibrosis resolution in post–liver transplant cholestatic hepatitis C virus (2018) (5)
- [Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. (2005) (5)
- Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak (2019) (5)
- Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon (2016) (4)
- How accurately and how early can we predict rapid fibrosis progression in hepatitis C virus–infected patients after liver transplantation? (2008) (4)
- [Functional abnormality of the diaphragm in the "shrinking lung" in systemic lupus erythematosus]. (1993) (4)
- Point‐of‐care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination (2021) (4)
- [Hepatic elastography. Position paper of the Catalan Society of Gastroenterology]. (2011) (4)
- Diagnosis of liver fibrosis in 2008. (2008) (4)
- Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. (2016) (4)
- LP24 : Safety, efficacy and impact on liver function of simeprevir (SMV) in combination with daclatasvir (DCV) or sofosbuvir (SOF) in patients with severe hepatitis C recurrence after liver transplantation (LT): results from compassionate use in europe (2015) (4)
- Association of chronic inflammation and perceived stress with abnormal functional connectivity in brain areas involved with interoception in hepatitis C patients (2019) (4)
- Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction? (2018) (4)
- SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program (2019) (3)
- Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients. (2018) (3)
- Chronic hepatitis C, depression and gender: a state of art (2015) (3)
- Complete Remission of Hypertrophic Discoid Cutaneous Lupus Erythematosus After Treatment of Chronic Hepatitis C With Direct-Acting Antivirals. (2020) (3)
- Hepatitis C Virus Envelope Protein E 2 Binds to CD 81 of Tamarins (2000) (3)
- The HBeAg-Negative "Gray Zone" Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients? (2020) (3)
- [87] EFFICACY OF ANTIVIRAL THERAPY ON DISEASE PROGRESSION IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY (2007) (3)
- Treatment of chronic hepatitis C. (2018) (3)
- Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution (2013) (3)
- Viral Hepatitis and Liver Transplantation: Pathogenesis, Prevention and Therapy of Recurrent Disease (2014) (3)
- Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct‐acting antiviral therapy—authors' reply (2017) (3)
- Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus‐specific CD8+ T cells after direct‐acting antiviral therapies (2020) (3)
- Value of duplex-doppler ultrasound findings in liver transplant recipients with poor graft function. (1996) (3)
- T2003 On-Treatment Response-Guided Therapy With Telaprevir Q8h or Q12h Combined With Peginterferon Alfa-2a or Peginterferon Alfa-2B and Ribavirin in Treatment-NaïVE Genotype 1 Hepatitis C (Study C208) (2010) (3)
- HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates (2022) (3)
- Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3–6) (2017) (3)
- Development of amyotrophic lateral sclerosis in the course of systemic lupus erythematosus (1992) (3)
- Modeling Early HCV Kinetics to Individualize Direct Acting Antivirals Treatment Duration in Patients with Advanced Cirrhosis (2016) (3)
- O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
- M12-999:ABT-450/r/ABT-267+ABT-333+Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection.: Abstract# 1325 (2014) (3)
- [The molecular biology of hepatitis C virus]. (2013) (2)
- 440 KLF12 POLYMORPHISM rs9543524 PREDICTS ANEMIA IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON AND RIBAVIRIN (2013) (2)
- 15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208 (2010) (2)
- 799 EFFICACY AND SAFETY OF TRIPLE-THERAPY WITH PEGINTERFERON-RIBAVIRIN, AND BOCEPREVIR AS COMPASSIONATE-USE IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: INTERIM-ANALYSIS AT 12 WEEKS (2013) (2)
- Advances in hepatitis C therapies (2015) (2)
- [33] HEPATITIS C VIRUS COMPARTMENTALIZATION AND INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION (2007) (2)
- 155 EFFICACY AND SAFETY OF STANDARD ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION (LT) (2013) (2)
- Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. (2017) (2)
- [Levofloxacin-induced autoimmune hepatitis. Description of a case]. (2014) (2)
- 108 EARLY ASSESSMENT OF LIVER STIFFNESS IDENTIFIES TWO DIFFERENT PATTERNS OF LIVER FIBROSIS PROGRESSION IN PATIENTS WITH HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2008) (2)
- Sustained Virologic Response Predicts Fibrosis Regression Measured by Fibrotest in HCV-Infected Patients (2016) (2)
- Primary herpes simplex virus type 1 infection with acute liver failure in solid organ transplantation: Report of three cases and review (2022) (2)
- P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV) (2014) (2)
- Red yeast rice extract: The risky trend of natural products. (2020) (2)
- Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in european patients who relapsed after previous interferon-based therapy: the promise trial (2014) (2)
- HCV: Alive and kicking in living donor liver grafts? (2005) (2)
- Eradication of hepatitis C virus in patients with decompensated cirrhosis does not improve the management of ascites after one year of follow-up (2018) (2)
- Risk of non‐tumoural portal vein thrombosis in patients with HCV‐induced cirrhosis after sustained virological response (2021) (2)
- [Genomic variability and natural history of hepatitis C virus infection]. (2002) (2)
- DAA therapy improves early post-liver transplant survival and induces significant changes in wait-list composition (2018) (2)
- O13 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN EUROPEAN PATIENTS WHO RELAPSED AFTER PREVIOUS INTERFERON-BASED THERAPY: THE PROMISE TRIAL (2014) (2)
- 83 Transient elastography to evaluate the severity of hepatitis C recurrence after liver transplantation (2006) (2)
- Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4 (2016) (2)
- Hepatitis C virus - A teacher of clinical research, cell biology and immunology. (2016) (2)
- Liver transplant immunosuppression during the COVID-19 pandemic☆ (2020) (2)
- Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. (2022) (2)
- 397 INDIVIDUAL PATIENT DATA META-ANALYSIS OF TRANSIENT ELASTOGRAPHY DIAGNOSTIC ACCURACY IN LIVER FIBROSIS ASSESSMENT OF CHRONIC HEPATITIS C PATIENTS (TE IPD STUDY) (2009) (2)
- Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. (2017) (2)
- “Targeting” hepatitis C after liver transplantation (2016) (2)
- A prospective study of nosocomial transmission of hepatitis C virus (HCV) in the liver unit of a tertiary care center (2003) (2)
- Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. (2017) (1)
- [Antiviral treatment in liver cirrhosis due to hepatitis C virus]. (2003) (1)
- High-resolution Hepatitis C virus (HCV) subtyping, using NS5B deep sequencing and 3 (2014) (1)
- First WDM-SDM Optical Network with Spatial Sub-Group Routing ROADM Nodes Supporting Spatial Lane Changes (2018) (1)
- Reply to: "Response to Mariño et al. J Hep 2019 Study: The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut". (2019) (1)
- Chronic viral hepatitis C (2012) (1)
- Nosocomial acquisition of the hepatitis C virus (2008) (1)
- P1239 HIGH SVR24 RATES WITH MERICITABINE (MCB), TELAPREVIR (TVR) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R) IN HCV G1-INFECTED PRIOR NULL RESPONDERS: RESULTS FROM DYNAMO 2 (2014) (1)
- The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy. (2020) (1)
- 260 SUCCESSFUL THERAPY WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN CAUSES A SUSTAINED DECREASE IN PORTAL PRESSURE IN PATIENTS WITH CHRONIC HEPATITIS C-RELATED CIRRHOSIS (2010) (1)
- O39 LONG TERM OUTCOME OF MILD HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A LARGE PROSPECTIVE STUDY (2014) (1)
- Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods (2016) (1)
- Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance (2021) (1)
- Serum and intrahepatic HBV markers and HBV-specific CD8 T cell responses after nucleos(t)ide analog therapy discontinuation in HBeAg-negative chronic hepatitis B patients (2020) (1)
- Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index (2020) (1)
- [Neutrophil anticytoplasmic antibodies in a patient with Wegener's granulomatosis: therapeutic implications of its detection and relation to clinical activity]. (1991) (1)
- Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
- Accepted Manuscript Clinical Trial Watch Clinical trial watch : reports from the Liver Meeting ( American Association for the Study of Liver Diseases (2015) (1)
- Early HCV viral kinetics after liver transplantation (2001) (1)
- 439 I148M PNPLA3 VARIANT PROMOTES STEATOSIS ACCORDING TO VIRAL AND IL28B GENOTYPE BUT DOES NOT AFFECT SUSTAINED VIRAL RESPONSE IN PATIENTS WITH HEPATITIS C (2013) (1)
- Unusual amino acid heterogeneity within the HCV-1b NS5a region for patients with hepatocellular carcinoma (2000) (1)
- P14: HepatiC, the viral hepatitis C patients management application and database (2013) (1)
- Interpreting liver stiffness in the cirrhotic range: What are we measuring? (2009) (1)
- Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon (2017) (1)
- Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B. (2022) (1)
- Miscellaneous I (1952) (1)
- Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. (2019) (1)
- HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment (2016) (1)
- Goodbye from Barcelona! (2004) (1)
- Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH) (2018) (1)
- Hepatitis C: the virus and studies of its lifecycle in cell culture systems (2008) (1)
- Higher prevalence of hepatitis E virus in autoimmune hepatitis: the role of false positive antibodies (2020) (1)
- Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents. (2022) (1)
- Living donor liver transplantation and hepatitis C: Lessons from the learning curve? (2007) (1)
- Improvement of sexuality after hepatitis C cure with direct acting antivirals (2020) (1)
- Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation. (2019) (1)
- P737 DEVELOPMENT OF A MODEL TO PREDICT PROGRESSION TO CIRRHOSIS IN CHRONIC HEPATITIS C PATIENTS WHO FAILED ANTIVIRAL THERAPY (2014) (1)
- P1135 ADDITION OF TELAPREVIR OR BOCEPREVIR TO PEG-RIB THERAPY INCREASES THE RISK OF INFECTIONS IN PATIENTS WITH HEPATITIS C-RELATED CIRRHOSIS (HCV-CH): A COMPARATIVE STUDY (2014) (1)
- [Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. (2012) (1)
- [Clinical features of viral hepatitis. Acute hepatitis. Chronic hepatitis. Hepatocellular carcinoma]. (1995) (1)
- Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents (2016) (1)
- [Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation]. (2012) (1)
- Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension (2018) (1)
- 808 MODELING HCV KINETICS DURING INTRAVENOUS SILIBININ MONOTHERAPY IN THE PERI-TRANSPLANT PERIOD (2013) (1)
- Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection (2018) (0)
- 924 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIED A NOVEL SUSCEPTIBILITY LOCUS GENE PBK (RS 17388536)FOR SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS BEARING IL28B GENOTYPE CC (2012) (0)
- Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy (2017) (0)
- Genetic evolution of hepatitis C virus after liver transplantation (2002) (0)
- Analysis of regulatory T cells frequency and phenotype in chronic hepatitis C patients undergoing interferon-free therapies (2020) (0)
- PS-017-Long-term impact of sustained virological response on systemic and pulmonary hemodynamics in HCV-cirrhotic patients with portal hypertension (2019) (0)
- 207 PERIPORTAL SINUSOIDAL FIBROSIS IS AN EARLY MARKER OF PORTAL HYPERTENSION AND SIGNIFICANT FIBROSIS IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2012) (0)
- Assessing sustained virological response and reinfection from dried blood spots within an on-site hepatitis C diagnosis and treatment model of care in a harm reduction centre (2022) (0)
- Chronic inflammation in hepatitis C patients is associated with increased perceived stress and abnormal connectivity between insula and basal ganglia (2018) (0)
- Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". (2019) (0)
- SVR to DAA does not affect the risk of portal vein thrombosis in patients with advanced chronic liver disease (2020) (0)
- Sustained Virologic Response Predicts Fibrosis Regression Measured by FibroTest in HCV-infected Patients: 828 (2016) (0)
- 830 INFECTION AND REPLICATION OF HEPATITIS C VIRUS IN BCLC HUMAN HEPATOCELLULAR CARCINOMA CELL LINES (2012) (0)
- Response to a double dose (40 mcg) and an accelerated schedule (0-1-2 months) of hepatitis B vaccine in patients with advance cirrhosis. A prospective study (2020) (0)
- 187 ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C: ADVANCED DONOR AGE AND FEMALE RECIPIENT GENDER IDENTIFY NON RESPONDERS AT HIGHER RISK OF GRAFT LOSS (2012) (0)
- FP899DEGREE OF LIVER INVOLVEMENT IN STABLE KIDNEY TRANSPLANT PATIENTS WITH HEPATITIS C INFECTION: A SINGLE-CENTER EXPERIENCE (2015) (0)
- P10 INTERFERON LAMBDA 4 (IFNL4) POLYMORPHISM PREDICTS RESPONSE TO HEPATITIS C TREATMENT AFTER LIVER TRANSPLANTATION (2014) (0)
- 1646 – Genetic Risk Factors For Interferon-induced Anxiety (2013) (0)
- Tu1021 Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation (2015) (0)
- P888 USEFULNESS OF ELF, IP10, FIBROSCAN AND THEIR COMBINATIONS IN THE EARLY PREDICTION OF SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2014) (0)
- 860 IMMUNOSTAINING AND 3D ANALYSES OF CORE AND NS5A HCV ANTIGENS IN LIVER BIOPSIES OF PATIENTS WITH HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2012) (0)
- Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts (2022) (0)
- FRI-435-Progression to cirrhosis is not infrequent in patients with Wilson’s disease despite treatment (2019) (0)
- P1152 APLASTIC ANEMIA DURING TRIPLE THERAPY (TT) IN PATIENTS WITH HCV-RELATED CIRRHOSIS (2014) (0)
- Differential changes in global and antigen-specific B cell frequencies and function associate with the outcome of HBV nucleos (t)ide analog treatment withdrawal (2022) (0)
- Can hepatitis A outbreaks in men who have sex with men be controlled? (2019) (0)
- Reply: (2013) (0)
- [Hepatitis C vaccine. Current status]. (1996) (0)
- Long-term immunological and clinical impact of HCV eradication with direct acting antivirals in patients with HCV-associated cryoglobulinemia vasculitis (2018) (0)
- [Molecular biology of hepatitis C virus: implications for the development of new therapies and prophylactic vaccine]. (2001) (0)
- 531 EARLY IDENTIFICATION OF TWO PATTERNS OF HEPATITIS C RECURRENCE (RAPID AND SLOW PROGRESSORS) AFTER LIVER TRANSPLANTATION: A PROSPECTIVE LONG-TERM FOLLOW-UP STUDY (2011) (0)
- 476 RISK OF VERTICAL TRANSMISSION OF HEPATITIS B (HBV) DESPITE NEONATAL PASIVE-ACTIVE IMMUNIZATION (2012) (0)
- Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations". (2017) (0)
- Increased lymphocyte trafficking and myeloid activation in patients with chronic hepatitis delta (2022) (0)
- Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals (2018) (0)
- Higher rates of virological relapse after nucleos (t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: results from a global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B Study) (2022) (0)
- 566 STUDY OF HEPATITIS C VIRUS SUPERINFECTION AFTER LIVER TRANSPLANTATION BY ULTRA-DEEP PYROSEQUENCING (2013) (0)
- O108 : Residual HCV-RNA in liver explants from patients undergoing sofosbuvir and ribavirin treatment while awaiting liver transplantation is not associated with HCV relapse (2015) (0)
- 14 EFFICAY AND SAFETY OF PEGYLATED INTERFERON AND RIBAVIRIN IN HCV-INFECTED PATIENTS AWAITING LIVER TRANSPLANTATION: A CASE-CONTROL STUDY (2008) (0)
- Value of intrahepatic HBV markers in virologically suppressed HBV and HDV infected patients (2022) (0)
- Deep-sequencing analysis demonstrates the persistence of pre-transplant HCV dominant variants within a more homogeneous quasispecies after liver transplantation (LT) in cholestatic hepatitis C patients (2015) (0)
- P1287 : Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by massive sequencing (2015) (0)
- Hepatitis C therapy and anticonvulsants. (2020) (0)
- Significant early and long-term improvement of neuropsychiatry symptomatology in HCV-infected patients after viral eradication with DAA (2022) (0)
- Low risk of viral hepatitis amongst patients with severe mental disorders. (2023) (0)
- SAT-245-Prospective evaluation of the impact of hepatitis C cure on sexual dysfunction (2019) (0)
- Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. (2016) (0)
- Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. (2019) (0)
- Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain (2020) (0)
- Beyond the achievement of sustained virological response after liver transplantation (2015) (0)
- Graft and Viral Outcomes in Retransplantation For HCV Recurrence and HCV Primary Liver Transplantation: A Case Control Study.: Abstract# A411 (2014) (0)
- Correspondence (2003) (0)
- Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria (2017) (0)
- Primary Sjögren’s Syndrome and Viruses (2011) (0)
- Assessing the Progression of Chronic HCV to Cirrhosis (2012) (0)
- Impact of sustained virologic response on liver fibrosis in recurrent hepatitis C after liver transplantation (2017) (0)
- Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitits B (2018) (0)
- The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy (2020) (0)
- Antiviral therapy can be avoided in most HBeAg-negative Caucasian patients in the Gray Zone (2018) (0)
- 766 Early lobular necrosis and living donor liver transplantation are strong predictors of severe HCV recurrence after liver (2003) (0)
- Author response: Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance (2021) (0)
- [Laboratory diagnosis of hepatitis B]. (2001) (0)
- Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men (2018) (0)
- 450 SERUM MARKERS OF LIVER FIBROSIS IDENTIFY PATIENTS WITH MILD AND SEVERE HEPATITIS C RECURRENCE DURING THE FIRST MONTHS AFTER LIVER TRANSPLANTATION (2009) (0)
- Is hepatitis B immunoglobulin necessary for hepatitis D prophylaxis after liver transplantation? A retrospective multicenter study of a cohort of 174 patients (2020) (0)
- Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver. (2022) (0)
- Considerations for optimizing Wilson’s disease patients’ long-term follow-up (2022) (0)
- [Predictive factors of response to interferon in chronic hepatitis]. (1995) (0)
- 1004 A simple model can predict response to interferon-ribavirin in genotype 1 chronic hepatitis C (2003) (0)
- Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study (2022) (0)
- [Treatment of chronic hepatitis C in cirrhosis of the liver]. (2002) (0)
- Early changes in brain structure, functional connectivity and neuropsychiatric symptoms after HCV infection cure with direct-acting antivirals (2021) (0)
- P0704 : Deep-sequencing analysis demonstrates the persistence of the pre-transplant HCV dominant variant within a more homogeneous quasispecies after liver transplantation in cholestatic hepatitis C patients (2015) (0)
- 1169 GENERATION OF PERMISSIVE BCLC5 CELL LINES FOR THE STUDY OF HCV REPLICATION: ROLE OF miR122 IN REPLICATION ENHANCEMENT (2013) (0)
- 748 LACK OF SUSTAINED VIROLOGICAL RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C IS ASSOCIATED WITH A SIGNIFICANT RISK OF PROGRESSION TO CIRRHOSIS (2008) (0)
- Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study). (2023) (0)
- Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease (2020) (0)
- Community-based HBV testing among west african migrants in greater Barcelona, Spain increases linkage to specialist care and vaccination: the HBV-COMSAVA model (2022) (0)
- Role of nosocomial hospital transmission in acute hepatitis C: Reply (2009) (0)
- [Treatment of viral hepatitis]. (1995) (0)
- IDDF2018-ABS-0109 SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 1–4 hcv-infected liver transplant recipients (2018) (0)
- Modeling hepatitis C virus kinetics during liver transplantation highlights the role of the liver in virus clearance (2020) (0)
- P1110 HIGH-RESOLUTION HCV SUBTYPING USING MASSIVE SEQUENCING AND PHYLOGENY, OPTIMAL ALTERNATIVE TO CURRENT METHODS (2014) (0)
- Partial restoration of brain structural and connectivity changes after HCV cure with direct acting antivirals (DAA) (2020) (0)
- O023 : Repeated measurement of non-invasive fibrosis markers to assess hepatitis C progression and clinical outcomes (2015) (0)
- Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions. (2014) (0)
- Residual HCV-RNA in liver explants from patients undergoing sofosbuvir and ribavirin treatment while awaiting liver transplantation is not associated with HCV relapse (2015) (0)
- Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir plus /-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials (2015) (0)
- Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation (2020) (0)
- Liver cirrhosis development and value of transient elastography among a large cohort of Wilsońs disease patients with a long-term follow-up in Spain (2020) (0)
- Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals (2017) (0)
- Contributing awareness of autoimmune hepatitis in HIV patients. (2019) (0)
- New antiviral treatments for chronic hepatitis C and health-related quality of life: A systematic review and meta-analysis (2017) (0)
- Cost-Effectiveness Analysis of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under “Real-Life” Conditions (2015) (0)
- Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test‐and‐treat program (2023) (0)
- Reply (2011) (0)
- THU-401-Changes in mortality due to chronic liver diseases in Spain during the period 2002-2016 (2019) (0)
- 849 INTERPLAY BETWEEN BASIC RESIDUES OF HEPATITIS C VIRUS GLYCOPROTEIN E2 WITH LIPOPROTEINS, VIRAL RECEPTORS AND NEUTRALIZING ANTIBODIES (2012) (0)
- Significant incidence of psyquiatric disorders despite rapid and positive impact of direct acting antivirals on quality of life (2017) (0)
- Clinical outcomes of patients delisted from the waiting list of liver transplantation after interferon-free antiviral therapy (2017) (0)
- Impact of Basal Comorbidities on the Overall Benefit of DAA Therapy in Hepatitis C (2016) (0)
- 186 AN INCREASED LIVER STIFFNESS MEASUREMENT ONE YEAR AFTER TRANSPLANTATION IS VERY ACCURATE AT PREDICTING CLINICAL OUTCOMES IN HEPATITIS C RECURRENCE (2012) (0)
- [Current epidemiology of viral hepatitis: who is affected and who can be protected?]. (2004) (0)
- Reply: To PMID 21294144. (2013) (0)
- 850 A GAUSSIA LUCIFERASE CELL-BASED SYSTEM TO ASSESS THE INFECTION OF CELL CULTURE- AND SERUM-DERIVED HEPATITIS C VIRUS (2012) (0)
- HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain (2022) (0)
- mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES Study (Chronic Hepatitis E Screening in patients with immune impairment and increased transaminases levels) (2023) (0)
- Genotypes 2 and 3 Relapse and Non‐Response (2011) (0)
- THU0298 Are Anti-La Antibodies A Potential Protection for Hepatitis C Virus Infection in SjÖGren Syndrome? Analysis in 663 Patients (2014) (0)
- HEPATITIS Liver Stiffness Identifies Two Different Patterns of Fibrosis Progression in Patients with Hepatitis C Virus Recurrence After Liver Transplantation (2010) (0)
- Plenary Sessions The World Transplant Congress 2014 Abstract Supplement is jointly published by the American Journal of Transplantation and Transplantation on behalf of the American Society of Transplant Surgeons, The Transplantation Society and the American Society of Transplantation (2014) (0)
- SAT-380-Liver-resident memory CD8 T cells do not egress into hepatic venous blood (2019) (0)
- Hemodynamic effects of direct-acting antivirals in patients with hepatitis-C virus-associated cirrhosis and portal hypertension non responsive to beta-blockers (2020) (0)
- Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing (2017) (0)
- Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). (2019) (0)
- Diagnosis of liver fi brosis in 2008 Diagnostic de la fi brose hépatique en 2008 (2008) (0)
- Red yeast rice extract: The risky trend of natural products (0)
- Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics (2020) (0)
- 156 HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: MAINTENANCE THERAPY WITH PEGYLATED INTERFERON IN NONRESPONDERS TO STANDARD THERAPY SLOWS THE DISEASE PROGRESSION AND IMPROVES SURVIVAL (2013) (0)
- P1008 A 5.9 kDa SERUM FRAGMENT OF FIBRINOGEN a-CHAIN IS A SPECIFIC SURROGATE MARKER OF ACTIVE FIBROGENESIS IN PATIENTS WITH LIVER DISEASE (2014) (0)
- P1158 EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP EARLY ACCESS PROGRAM (2014) (0)
- Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort (2016) (0)
- Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question (2021) (0)
- Molecular characterization of hepatocellular carcinoma in Mongolia delineates unique genomic features (2020) (0)
- HepCom: impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C (2017) (0)
- Control of occult hepatitis B virus infection (2022) (0)
- 798 CELL CULTURE REPLICATION OF A GENOTYPE 1B HEPATITIS C VIRUS ISOLATE CLONED FROM A PATIENT WHO UNDERWENT LIVER TRANSPLANTATION (2011) (0)
- Recurrent Disease and Management in Liver Transplantation (2008) (0)
- Abstracts from EIR School ES01–ES25 (2012) (0)
- Natural History of Chronic Hepatitis B Virus Infection in Inactive Carriers and in “Gray Zone” Patients (2016) (0)
- 30 A COMBINATION OF BASELINE VARIABLES INCLUDING IL28B POLYMORPHISM CAN ACCURATELY PREDICT RESPONSE TO ANTIVIRAL TREATMENT IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2011) (0)
- POSITION PAPER OF THE CATALAN SOCIETY OF GASTROENTEROLOGY ABOUT HEPATIC ELASTOGRAPHY 2022. (2022) (0)
- Correspondence (2003) (0)
- Liver-resident T cell PD-1 correlates with intrahepatic HBV-DNA and is reduced following prolonged antiviral therapy (2022) (0)
- Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]. (2020) (0)
- 558 HCV KINETICS DURING AND AFTER THE ANHEPATIC PHASE: IS THE LIVER THE PRIMARY SITE FOR HCV CLEARANCE? (2013) (0)
- Hepatitis C therapy and anticonvulsants (2021) (0)
- A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients (2017) (0)
- P0061 : Treatment with new all-oral direct acting antivirals in HCV-recurrence in liver transplant-setting induces a reduction of immunosuppressive drug levels (2015) (0)
- Considerations for optimizing Wilson´s Disease patients´ long-term follow-up. (2021) (0)
- Viral and ALT kinetics after nucleos (t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study) (2022) (0)
- Antiviral treatment in cirrhosis associated with hepatitis C virus before and after liver transplantation. (2004) (0)
- Reply to ''The extrahepatic contribution to HCV plasma viremia'' (2006) (0)
- 643 EXPRESSION OF HEPATITIS C VIRUS (HCV) RECEPTORS IN GRAFTS FROM HCV-INFECTED LIVER TRANSPLANT RECIPIENTS (2010) (0)
- Proteomic identification of serum factors that correlate with reduction of HVPG following curative treatment for hepatitis C virus infection (2020) (0)
- Safety Comparison of 12- And 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From Turquoise-II: 442 (2014) (0)
- 781 IDENTIFICATION OF HEPATITIS C VIRUS (HCV) GLYCOPROTEIN E2 DOMAINS AND RESIDUES RESPONSIBLE FOR INTERACTION WITH HEPARAN SULFATE (2011) (0)
- 169 EARLY EVALUATION OF HISTOLOGICAL MARKERS OF FIBROSIS AND CELLULAR PROLIFERATION IN LIVER TRANSPLANT PATIENTS WITH HCV RECURRENCE (2013) (0)
- [Telaprevir in HCV-monoinfected patients with failure to prior treatment]. (2013) (0)
- Health-related Quality of Life, Psychiatric History, and HIV Comorbidity in Hepatitis C Patients Receiving Antiviral Treatment: a Systematic Review (2015) (0)
- Juan Rodés, M.D., Ph.D. (1938-2017): Excellence and leadership. (2017) (0)
- Neutrophil function in patients with chronic hepatitis C (CHC) undergoing triple antiviral therapy (TT) with first and second generation protease inhibitors (PI) (2015) (0)
- 451 CLINICAL, HISTOLOGICAL AND HEMODINAMIC OUTCOMES IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS TREATED WITH PEGILATED INTERFERON PLUS RIBAVIRIN (2009) (0)
- An uncommon presentation of alcoholic liver disease (2018) (0)
- P1186 TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE-1 HCV INFECTION: PHARMACOKINETIC RESULTS OF ADJUSTED DOSING WITH TACROLIMUS OR CYCLOSPORINE IN THE TELAPREVIR REPLACE STUDY (2014) (0)
- Screnning of viral hepatitis in mental disorder patients: Psiqui-Clinic Programme (2022) (0)
- Treatment of Hepatitis C Before Liver Transplantation (2014) (0)
- Massive hemolysis complicating acute granulomatous hepatitis (2018) (0)
- Baseline features of hepatitis C patients associated to prescription of pangenotypic antiviral treatments: results from the real-world Spanish Hepa-C registry (2020) (0)
- P0785 : First real clinical practice data in Spain on sofosbuvir, simeprevir and daclatasvir in post-transplant HCV recurrence: The HepatiC registry experience (2015) (0)
- Persistent Transcriptional Alterations after Hepatitis C Virus Elimination in Cell Culture (2020) (0)
- Noninvasive tests in the post–liver transplantation setting (2007) (0)
- P227 P-BODY FORMATION IS IMPAIRED IN LIVERS FROM HCV-INFECTED PATIENTS (2014) (0)
- [Usefulness of liver stiffness measurement after antiviral response in chronic hepatitis C]. (2013) (0)
- Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection - Authors' reply. (2017) (0)
- P0880 : Pharmacogenomic study to predict ribavirin and protease-inhibitor-related anemia in hepatitis C (2015) (0)
- FRI-147-Gradual restoration of HCV-specific CD8+ T cell frequency but persistence of altered phenotype in cirrhotic HCV-infected patients after successful direct-acting antiviral therapy (2019) (0)
- Antiviral therapy in HCV-infected cirrhotic patients awaiting liver transplantation (2009) (0)
- Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries. (2023) (0)
- 210 SUSTAINED VIROLOGICAL RESPONSE WITH PEG-INTERFERON alfa-2a AND RIBAVIRIN DECREASES PORTAL PRESSURE GRADIENT AND PREVENTS CLINICAL DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C RELATED CIRRHOSIS (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Xavier Forns?
Xavier Forns is affiliated with the following schools:
